With its focus on emerging concerns of kinase and GPCR-mediated
antitarget effects, this vital reference for drug developers addresses
one of the hot topics in drug safety now and in future.
Divided into three major parts, the first section deals with novel
technologies and includes the utility of adverse event reports to drug
discovery, the translational aspects of preclinical safety findings,
broader computational prediction of drug side-effects, and a description
of the serotonergic system. The main part of the book looks at some of
the most common antitarget-mediated side effects, focusing on
hepatotoxicity in drug safety, cardiovascular toxicity and signaling
effects via kinase and GPCR anti-targets. In the final section, several
case studies of recently developed drugs illustrate how to prevent
anti-target effects and how big pharma deals with them if they occur.
The more recent field of systems pharmacology has gained prominence and
this is reflected in chapters dedicated to the utility in deciphering
and modeling anti-targets. The final chapter is concerned with those
compounds that inadvertently elicit CNS mediated adverse events,
including a pragmatic description of ways to mitigate these types of
safety risks.
Written as a companion to the successful book on antitargets by Vaz and
Klabunde, this new volume focuses on recent progress and new classes,
methods and case studies that were not previously covered.
